Products Carvedilol is commercially available in tablet form (Dilatrend, generic). It has been approved in many countries since 1995. Carvedilol is also combined with ivabradine fixed (Carivalan). Structure and properties Carvedilol (C24H26N2O4, Mr = 406.5 g/mol) is a racemate, with both enantiomers participating in the pharmacological effects. It exists as a white crystalline powder that … Carvedilol
Products Tadalafil is commercially available in the form of film-coated tablets (Cialis, Adcirca, generics). It has been approved in many countries since 2004. Generics were registered in 2016 and came on the market in 2019. This article is related to erectile dysfunction treatment. Structure and properties Tadalafil (C22H19N3O4, Mr = 389.4 g/mol) exists as a … Tadalafil
Products Tafamidis was approved in the EU in 2011, in the US in 2019, and in many countries in 2020 in soft capsule form (Vyndaqel). Structure and properties Tafamidis (C14H7Cl2NO3, Mr = 308.1 g/mol) is present in the drug either as tafamidis meglumine or as tafamidis. Effects Tafamidis (ATC N07XX08) is a selective stabilizer of … Tafamidis
Products Moxifloxacin is commercially available in the form of film-coated tablets, as an infusion solution, and eye drops (Avalox, Vigamox eye drops). It has been approved in many countries since 1999. Generic versions of the tablets went on sale in 2014. This article refers to oral administration; see also moxifloxacin eye drops. Structure and properties … Moxifloxacin
Products Ambrisentan is commercially available in the form of film-coated tablets (Volibris). It has been approved in many countries since 2008. Generic versions were registered in 2020. Structure and properties Ambrisentan (C22H22N2O4, Mr = 378.4 g/mol) is a dimethylpyrimidine, diphenyl and propionic acid derivative and exists as a white crystalline powder that is practically insoluble … Ambrisentan
Products Olmesartan is commercially available in the form of film-coated tablets (Olmetec, Votum, fixed combinations with amlodipine and hydrochlorothiazide). It has been approved in many countries since 2005. Generics were registered in 2016 and went on sale in 2017. Structure and properties Olmesartan is present in drugs as olmesartan medoxomil (C29H30N6O6, Mr = 558.6 g/mol), … Olmesartan
Products Olanzapine is commercially available as film-coated tablets, meltable tablets, and powder for solution for injection (Zyprexa, generics). It has been approved in the U.S. and EU since 1996 and in many countries since 1997. Generic versions entered the market in 2012. Structure and properties Olanzapine (C17H20N4S, Mr = 312.4 g/mol) belongs to the thienobenzodiazepine … Olanzapine
Products Lisdexamphetamine (LDX) was approved in many countries in March 2014 in capsule form (Elvanse). It has been available in the United States since 2007 (Vyvanse). The dosage form is non-retarded, unlike other ADHD medications. Continuous release is achieved with the conversion of the prodrug. Lisdexamphetamine is legally classified as a narcotic and therefore requires … Lisdexamphetamine
Products Lisinopril is commercially available in tablet form as a monopreparation (Zestril, generic) and as a fixed combination with hydrochlorothiazide (Zestoretic, generic). It has been approved in many countries since 1989. Structure and properties Lisinopril (C21H31N3O5, Mr = 405.49 g/mol) is present in drugs as lisinopril dihydrate, a white crystalline powder that is soluble in … Lisinopril: Drug Effects, Side Effects, Dosage and Uses
Products Edoxaban was approved in many countries and in the United States in 2015 in film-coated tablet form (Lixiana, some countries: Savaysa). In Japan, edoxaban was approved as early as 2011. Structure and properties Edoxaban (C24H30ClN7O4S, Mr = 548.1 g/mol) is present in the drug as edoxabantosilate monohydrate, a white to pale yellow powder that … Edoxaban
Products Linezolid is commercially available as an infusion solution, in the form of film-coated tablets, and as granules for preparation of a suspension (Zyvoxid, generics). It has been approved in many countries since 2001. Structure and properties Linezolid (C16H20FN3O4, Mr = 337.3 g/mol) was the first agent developed from the oxazolidinone group. It is structurally … Linezolid
Products Liraglutide was approved in many countries in 2009 as a solution for injection in a prefilled pen (Victoza). In 2014, a fixed-dose combination with insulin degludec was released (Xultophy); see IDegLira. In 2016, Saxenda was registered for the treatment of overweight and obesity. Its related successor, semaglutide, unlike liraglutide, only needs to be injected … Liraglutide
